Abstract
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.
Original language | English (US) |
---|---|
Pages (from-to) | 821-829 |
Number of pages | 9 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 10 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2012 |
ASJC Scopus subject areas
- Oncology